OVERVIEW

•Inflammation within blood vessel walls causing end-organ damage often a/w systemic sx; may be primary or secondary (eg, infection, malignancy) in etiology

•Classified by size of _predominant_ vessel affected (_Arthritis Rheum_ 2013;65:1); overlap of vessel size affected is common

•臨床表現 based on size of vessels involved; constitutional sx (low-grade fever, fatigue, weight loss, myalgias, anorexia) common to all

![](https://i.imgur.com/egPBrFs.png)

TAK, Takayasu’s arteritis; GCA, giant cell arteritis; PAN, polyarteritis nodosa; ANCA-assoc. is GPA, EGPA, & MPA; IC, immune complex small-vessel vasculitis (eg, HSP, cryoglobulinemia); GN, glomerulonephritis.

LARGE-VESSEL VASCULITIS

Takayasu’s arteritis (“pulseless disease”)

•**Arteritis of aorta and its branches** → **stenosis/aneurysm** → claudication; onset <50 y

•Pattern of involvement: aorta and branches; most often **subclavian** and **innominate arteries** (>90%), as well as carotid, coronary, renal, pulmonary (~50%)

•流行病學: most common in **Asia;** ♀:♂ ~9:1; **age** <**50 y**

•臨床表現 and physical findings (_Circ_ 2015;132:1701)

Systemic inflamm with **fever**, **arthralgias**, wt loss

Vessel inflamm with pain & tenderness, ↓ **& unequal pulses/BPs in extremities**, **bruits**, limb claudication, renovascular HTN (>50%), neurogenic syncope; Ao aneurysm ± AI

“Burnt out” or fibrotic period (eg, vascular stenosis)

•Dx studies: ↑ ESR (75%), CRP; **arteriography** (MRA, CTA) → occlusion, stenosis, irregularity, and aneurysms; carotid U/S Doppler studies; PET-CT; **pathology** → focal panarteritis, cellular infiltrate with _granulomas_ and giant cells (bx not required for dx)

•Rx: **steroids** ± MTX or AZA; anti-TNF (2nd line, _Autoimmun Rev_ 2012;11:678); anti-IL-6 ? effective (_J Autoimmun_ 2018;91:55); ASA; surgical/endovascular revasc (_Circ_ 2008;69:70)

•Monitoring: MRA or PET-CT (_Arth Rheum_ 2012;64:866); ESR/CRP (_Ann Rheum Dis_ 2009;68:318)

Giant cell arteritis (GCA) (_JAMA_ 2016;315:2442)

•**Granulomatous arteritis of aorta/branches** with predilection for **temporal artery**

•Pattern of involvement: **extracranial branches of carotid artery**, esp. temporal artery (thus also called **temporal arteritis**); aorta and/or its branches in 10–80%

•90% of 病人 with GCA are >60 y, peak incidence at 70–80 y, extremely rare <50 y; ♀:♂ = 3:1

•臨床表現 (_NEJM_ 2014;371:50)

Constitutional sx: **fevers**, fatigue, wt loss

### Temporal artery (TA) → **headache, tender TAs** and scalp, absent TA pulse

Ophthalmic artery (20%) → optic neuropathy, diplopia, amaurosis fugax, blindness

Facial arteries → **jaw claudication**

Large vessel vasculitis → intermittent claudication of extremities; thoracic aorta aneurysm

### Strong association with PMR; ~50% of 病人 with GCA ultimately received PMR diagnosis

•Dx studies: ↑ **ESR** (Se 84%, Sp 30%), ↑ CRP (Se 86%, Sp 30%), anemia

### temporal artery bx _whenever GCA suspected_ (Se ≤85%); 1–2 cm ± bilat to ↑ yield (3– 7% discordance) (_Ann Rheum Dis_ 2009;68:318) → vasculitis & _granulomas_

if suspect aortitis or lg-vessel involvement (BP Δ or bruits) → MRI/MRA or PET-CT

•Rx: **steroids**: _do not await bx/path results to begin!_ Have at least 2 wk to bx without Δ results. Prednisone 40–60 mg/d with _slow_ taper, ASA daily; consider IV steroid pulse if vision threatened. Adding tocilizumab helps achieve sustained remission (_NEJM_ 2017;377:317).

•**Polymyalgia rheumatica** (_JAMA_ 2016;315:2442; _Lancet_ 2017;390:1700)

Seen in 50% of GCA 病人; 15% of 病人 with PMR develop GCA

Age ≥50 y; ESR >40 mm/h (and/or ↑ CRP); _bilateral_ **_pain & morning stiffness_** (>30 min), involving 2 of 3 areas: neck or torso, shoulders or prox. arms, hips or prox. thighs; nighttime pain; ± subdeltoid bursitis on U/S; exclude other causes of sx (eg, RA); 正常 CK

Rx: pred 12.5–25 mg/d; if 臨床improvement, initiate slow taper. If no improvement, ↑ dose. Consider MTX if at high risk for steroid side effects (_Ann Rheum Dis_ 2015;74:1799).

•Follow 臨床status & ESR/CRP (_Ann Rheum Dis_ 2009;68:318); ~1/3 relapse over 2 y (_J Rheum_ 2015;42:1213)

MEDIUM-VESSEL VASCULITIS

Polyarteritis nodosa (“classic” PAN) (_Arth Rheum_ 2010;62:616)

•**Necrotizing nongranulomatous vasculitis of medium and small arteries** (w/ muscular media) without glomerulonephritis or capillary involvement (ie, no DAH), not a/w ANCA

•流行病學: ♂ > ♀; average age of onset ~50 y; 1° vs. 2° (**HBV** > HCV; ~10%)

•臨床表現

Constitutional sx (80%): wt loss, **fever**, fatigue

Neuro (79%): **mononeuritis multiplex**, peripheral neuropathies, stroke

Musculoskeletal (64%): **extremity pain**, **myalgias**, arthralgias, arthritis

Renal (51%): **HTN**, hematuria, proteinuria, renal failure, _glomerulonephritis unusual_

GI (38%): **abd pain**, GIB/infarction, cholecystitis; GU (25%): ovarian or testicular pain

Skin (50%): **livedo reticularis**, purpura, nodules, ulcers, Raynaud’s

Ophthalmic (9%): retinal vasculitis, retinal exudates, conjunctivitis, uveitis

Cardiac (22%): coronary arteritis, cardiomyopathy, pericarditis

Pulmonary: rare; **if lung involvement, suspect other vasculitis**

•Dx studies: ↑ ESR/CRP, ANCA, HBV testing, ↓ C3/C4 if HBV-associated

### Angiogram (mesenteric or renal vessels) → **microaneurysms** & focal vessel narrowing

CTA may be adequate to make dx, but conventional angiogram is most sensitive

### Biopsy (sural nerve, skin, or affected organ) → vasculitis of small- and medium-vessel arteries with fibrinoid necrosis _withoutut granulomas_

•Rx: based on severity; **steroids** ± DMARD (eg, MTX or CYC); antivirals if a/w HBV

ANCA-ASSOCIATED SMALL-VESSEL VASCULITIS

_Microvascular vasculitis (eg, capillaries, postcapillary venules, & arterioles)_

![](https://i.imgur.com/d9oWUjs.png)

aPredominant ANCA type; either p- or c-ANCA can be seen in all three diseases (_NEJM_ 2012;367:214).

bGPA is formerly Wegener’s granulomatosis and EGPA is formerly Churg-Strauss.

Differential diagnosis of ANCA (_Lancet_ 2006;368:404)

•**anti-PR3 (c-ANCA):** GPA, EGPA, microscopic polyangiitis (rarely), levamisole (contaminant in cocaine) both c- & p-ANCA ⊕

•**anti-MPO (p-ANCA):** microscopic polyangiitis, EGPA, GPA, drug-induced vasculitis, nonvasculitic rheumatic dis., levamisole (contaminant in cocaine) both c- & p-ANCA ⊕

•**Atypical ANCA patterns:** drug-induced vasculitis, nonvasculitic rheumatic diseases,

ulcerative colitis, primary sclerosing cholangitis, endocarditis, cystic fibrosis

Granulomatosis with polyangiitis (GPA, formerly Wegener’s granulomatosis)

•**Necrotizing granulomatous systemic vasculitis** frequently affecting nose, sinuses and/or upper respiratory tract in addition to kidneys, lungs, etc.

•流行病學: any age, but ↑ incidence in young and middle-aged adults; ♂=♀

•臨床表現

Constitutional: fever, fatigue, malaise, anorexia, **unexplained wt loss**

### Respiratory (90%): Upper: **recurrent sinusitis**, rhinitis, oral/nasal ulcers, **nasal crusting**, **saddle-nose deformity**, otitis, hearing loss, subglottic stenosis;

Lower_:_ **pulm. infiltrates**, **nodules**, **pulm. hemorrhage**, hemoptysis, pleurisy

### Renal (80%): **RPGN** (pauci-immune), RBC casts, dysmorphic RBCs, hematuria

Ocular (50%): episcleritis, scleritis, uveitis, orbital granulomas → proptosis, corneal ulcer

Neurologic: cranial and peripheral neuropathies, **mononeuritis multiplex**

Skin (50%): palpable purpura, livedo reticularis

Hematologic: ↑ incidence DVT/PE (20×) when disease active (_Ann Intern Med_ 2005;142:620)

•Dx studies: **90%** ⊕ **ANCA** (80% PR3, 20% MPO), less Se in limited upper-airway disease

CXR or CT → nodules, infiltrates, cavities; sinus CT → sinusitis ± bone erosions

↑ BUN & Cr, proteinuria, hematuria; sediment with RBC casts, dysmorphic RBCs

Biopsy → necrotizing granulomatous inflammation of arterioles, capillaries, veins

•治療: assess disease severity with BVAS/WG score (_Arth Rheum_ 2001;44:912)

### Mild disease (no end-organ dysfxn; BVAS 0-3): **MTX** + **steroids** (_Arth Rheum_ 2012;64:3472)

### Severe disease (end-organ damage incl. pulm hemorrhage, RPGN etc.; BVAS >3):

_Induction:_ [**RTX** 375 MG/m2/wk × 4 wk _or_ **CYC** 2 mg/kg/d × 3–6 mo or pulse 15 mg/kg q2–3wk] + **steroids** 1 g IV × 3 d → 1–2 mg/kg/d (_NEJM_ 2005;352:351, 2010;363:211, & 2013;369:417; _Annals_ 2009;150:670; _Ann Rheum Dis_ 2015;74:1178)

If RPGN: ± plasma exchange to ? ↓ risk of ESRD (_Am J Kidney Dis_ 2011;57:566)

_Maintenance:_ RTX q6mo superior to AZA or watchful waiting (_Arth Rheum_ 2012;64:3760; _NEJM_ 2014;371:1771)

**Relapse:** mild → steroids ± MTX or AZA; severe → reinduce with steroids + RTX or CYC

↑ ANCA without 臨床evidence of flare should _not_ prompt Δ Rx (_Annals_ 2007;147:611)

Microscopic polyangiitis (MPA) (_Rheum Dis Clin North Am_ 2010;36:545)

•Similar to GPA, but **w/o ENT/airway involvement & nongranulomatous**

•流行病學: ♂ > ♀; avg onset 50–60 y

•臨床表現: similar to GPA _w/o upper respiratory involvement;_ **Renal** (80–100%): glomerulonephritis **Pulmonary** (25–50%): pulmonary capillary alveolitis, pulmonary fibrosis Constitutional and neuro sx similar to GPA; skin lesions (eg, palpable purpura) in 30–60%

•Dx studies: **70%** ⊕ **ANCA** (almost all anti-MPO)

biopsy → necrotizing, **nongranulomatous** inflammation of small vessels, pauci-immune (minimal deposition of complement or Ig; contrast with HSP, cryoglobulinemia, etc.)

urine sediment and CXR findings similar to those seen in GPA

•治療: as for GPA; ↓ relapse rate compared to GPA

Eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss)

•Similar to GPA with more frequent **cardiac involvement**, a/w **asthma** and **eosinophilia**

•流行病學: rare; can present at any age (typically 30–40 y); a/w HLA-DRB4

•臨床表現 (_Curr Rheumatol Rep_ 2011;13:489)

Initial sx: **asthma**, sinusitis, allergic rhinitis (new asthma in adult raises suspicion)

Eosinophilic infiltrative disease: transient **pulm infiltrates**, gastroenteritis, or esophagitis

Systemic small-vessel vasculitis: **neuropathy** (mononeuritis multiplex), renal (glomerulonephritis), skin (palpable purpura, petechial, nodules)

**Cardiac:** coronary arteritis, myocarditis, CHF, valvular insufficiency (_Medicine_ 2009;88:236)

•Dx studies: 50% ⊕ ANCA (MPO > PR3), **eosinophilia** (5–10 k/µL, 80–100%),

biopsy → microgranulomas, fibrinoid necrosis, and thrombosis of small arteries and veins with eosinophilic infiltrates

•治療: high-dose **steroids** + CYC (if severe); anti-IL5 (mepolizumab) for refractory/relapsing (_NEJM_ 2017;376:1921)

Renal-limited vasculitis

•Small vessel pauci-immune vasculitis causing RPGN without other organ involvement

•Dx studies: 80% ⊕ ANCA (MPO > PR3); biopsy with pauci-immune GN ± granulomas

•治療 identical to that for GPA/MPA

IMMUNE COMPLEX (IC)–ASSOCIATED SMALL-VESSEL VASCULITIS

Henoch-Schönlein purpura (HSP)

•**IgA-mediated** vasculitis with predilection for **skin**, **GI tract**, and **kidneys**

•流行病學: ♂ > ♀, children > adults, onset in winter > summer

•May develop after upper respiratory tract infection (esp. _Strep_) or drug exposure

•臨床表現

### Palpable purpura on extensor surfaces (lower extremity first) & buttocks

### Polyarthralgias (nondeforming) esp. involving hips, knees, & ankles

Colicky **abdominal pain** ± GIB or intussusception

Nephritis ranging from **microscopic hematuria** & proteinuria to ESRD

•Dx studies: **skin bx with immunofluorescence** → **leukocytoclastic vasculitis** with **IgA**

and **C3** deposition in vessel wall; renal bx → mesangial IgA deposition

•治療: often self-limiting over 4 wk; steroids ± DMARDs for renal or severe disease

Connective tissue disease–associated vasculitis

•Small-vessel vasculitis a/w **RA**, **SLE** or **Sjögren’s syndrome**

•臨床表現

Distal arteritis: digital ischemia, livedo reticularis, palpable purpura, cutaneous ulceration

Visceral arteritis: pericarditis and mesenteric ischemia

Peripheral neuropathy

•Dx studies: skin/sural nerve bx, EMG, angiography; ↓ C′ in SLE; ⊕ RF or anti-CCP in RA

•治療: steroids, cyclophosphamide, MTX (other DMARDs)

Cutaneous leukocytoclastic angiitis

•Most common type of vasculitis; heterogeneous group of 臨床syndromes due to **IC deposition** in capillaries, venules, and arterioles; includes **_hypersensitivity vasculitis_**

•原因

Drugs: PCN, ASA, amphetamines, levamisole, thiazides, chemicals, immunizations, etc.

Infections: _Strep_, _Staph_, endocarditis, TB, hepatitis

Malignancy (paraneoplastic)

•臨床表現: abrupt onset of **palpable purpura** and **transient arthralgias** after exposure to the offending agent; visceral involvement rare but can be severe

•Dx studies: ↑ ESR, ↓ complement levels, eosinophilia; ✔ U/A; **skin biopsy** → leukocytoclastic vasculitis **_w/o IgA deposition_** in skin (to distinguish from HSP)_;_ if etiology not clear, consider ANCA, cryoglobulins, hepatitis serologies, ANA, RF

•治療: withdrawal of offending agent ± rapid prednisone taper

Behçet’s syndrome (_Curr Rheum Opin_ 2010;12:429)

•**Systemic vasculitis** affecting all vessel sizes, a/w painful **oral and/or genital ulcers**

•流行病學: usually young adults (25–35 y); a/w HLA-B51 in areas of highest prevalence on the old Silk Road (Turkey, Middle East, and other Asian countries)

•Classification criteria (#1 + ≥2 others is 91% Se & 96% Sp; _Lancet_ 1990;335:1078)

1. Recurrent **oral aphthous ulceration** (≥3× in 1 y, usually 1st manifestation)

2. Recurrent **genital ulceration** (labia in females, scrotum in males)

3. **Eye lesions:** uveitis, scleritis, retinal vasculitis, optic neuritis; _may threaten vision_

4. **Skin lesions:** pustules, papules, folliculitis, erythema nodosum (scarring)

5. ⊕ pathergy test (prick forearm with sterile needle → pustule) (not sensitive in Caucasians)

•Other 臨床表現: most recur but are not chronic

Arthritis: mild, ± symmetric, nondestructive, involving knees and ankles

Neurologic: usually involvement of midbrain parenchyma; peripheral neuropathy rare

Vascular: superficial or deep vein thrombosis (25%); arterial stenosis, occlusion, and aneurysm can also occur; low incidence of thromboembolism

•Dx studies: ↑ ESR/CRP; ulcer swab to 排除 HSV; ulcer bx nonspecific; ophtho eval if sx

•治療 (_Rheumatology_ 2007;46:736; _Ann Rheum Dis_ 2008;67:1656 & 2009;68:1528)

Mucocutaneous:

Mild: **topical steroids**, **colchicine** (esp. for erythema nodosum), dapsone, apremilast (PDE-4 inhib) for oral ulcers and ? genital ulcers (_NEJM_ 2015;372:1510),

Severe: oral steroids, steroid-sparing agents

Arthritis: NSAIDs, colchicine, steroids, steroid-sparing agents

Ocular: **topical and/or systemic steroids** ± steroid-sparing agents

Steroid-sparing: AZA, anti-TNF, CYC (large vessel and CNS ds), CsA, MTX, IFNα-2A,

Venous thrombosis: steroids and anticoagulation (careful if aneurysm present)

